Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04886076 · ClinicalTrials.gov registry record

Sleep Profiles in REM Sleep Behavior Disorder

A clinical trial of Rapid Eye Movement Sleep Behavior Disorder, sponsored by Massachusetts General Hospital.

Active
Registry status
30
Enrollment target
1
Study location

NCT04886076: Active study of Rapid Eye Movement Sleep Behavior Disorder, sponsored by Massachusetts General Hospital.

NCT04886076 is a study of Rapid Eye Movement Sleep Behavior Disorder that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04886076, a study of Rapid Eye Movement Sleep Behavior Disorder, is active but no longer recruiting, sponsored by Massachusetts General Hospital.

ACTIVE NOT RECRUITING
Registry status
30 participants
Enrollment target
1
Study location

Study Summary

Rapid eye movement (REM) sleep behavior disorder (RBD) is a sleep disorder in which you act out dreams during REM sleep. Sleep disturbances are very common in RBD, where they negatively impact patients' quality of life and safety. One of the known causes of sleep disturbance is the impairment of the "circadian rhythm", or the human sleep/wake cycle. The purpose of this study is to examine the role of disruption of the circadian rhythm in the development of RBD.

Primary Outcome

amplitude and area under the curve (AUC) of serum melatonin and clock gene expression

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2018-12-07
Est. Completion 2026-11
Massachusetts General Hospital

2,032 total trials

What the registry record for NCT04886076 still lists

NCT04886076 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.

The record links to 1 condition, with Rapid Eye Movement Sleep Behavior Disorder appearing as the primary indexed condition, and to 0 interventions.

NCT04886076 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04886076 about?

NCT04886076 is a clinical study titled "Sleep Profiles in REM Sleep Behavior Disorder". Rapid eye movement (REM) sleep behavior disorder (RBD) is a sleep disorder in which you act out dreams during REM sleep. Sleep disturbances are very common in RBD, where they negatively impact patients' quality of life and safety. One of the known causes of sleep disturbance is the impairment of the...

What is the current status of trial NCT04886076?

This trial is currently active not recruiting. The enrollment target is 30 participants. The study started on 2018-12-07. Estimated completion is 2026-11.

What conditions does trial NCT04886076 study?

This clinical trial studies the following conditions: Rapid Eye Movement Sleep Behavior Disorder.

Who is sponsoring clinical trial NCT04886076?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04886076 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04886076, the US trial registry maintained by the National Library of Medicine. NCT04886076 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.